Forxiga smile with first PMS result conducted on large Koreans
The post-marketing surveillance(PMS) result of ‘Forxiga(generic name: dapagliflozin),’ a SGLT-2 inhibitor whose research was conducted on 1,500 Korean diabetes type 2 patients, has been released. The 24-week researchees’ glycated hemoglobin and weight ware researched to drop 0.87% and 1.71kg down...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
